- Cladribine capsules have the potential to be the first oral treatment for people living with generalised Myasthenia Gravis
- Cladribine capsules has received Fast Track designation and Orphan Drug Designation by the US FDA
- Merck has established an MG patient council to provide insights on how to best meet the needs of patients in the gMG rare disease community
Merck has announced that the US Food and Drug Administration (FDA) has granted Fast Track designation to cladribine capsules for the treatment of generalised Myasthenia Gravis (gMG). The therapy, already recognised with Orphan Drug Designation, is being developed as a potential first oral treatment option for people living with gMG.
Cladribine capsules are currently being evaluated in the global Phase 3 MyClad trial, which is designed to assess their safety and efficacy in 264 patients. The drug targets B and T cells thought to contribute to the production of autoantibodies that damage the neuromuscular junction. If approved, the short-course, infrequently administered oral regimen could reduce treatment burden by allowing patients to take the therapy at home.
Merck’s patient-directed development strategy has been central to the programme. To ensure the clinical trial reflects the needs and experiences of people living with gMG, the company has established a dedicated MG patient council and is working with more than 20 advocacy groups globally. Patient insights have influenced study design, recruitment materials and considerations around future packaging.
| Sign up to the ACNR email newsletter here |
The company is also collaborating with Ad Scientiam to explore digital tools that could improve disease monitoring in real-world settings. A multi-centre pilot study will assess an investigational software as a medical device capable of integrating wearable data, smartphone-based functional testing and electronic patient-reported outcomes. The aim is to detect changes in disease trajectory more accurately and support personalised disease management.
Merck states it remains committed to incorporating patient perspectives throughout the development process and will share results from the MyClad trial upon its completion. The combination of Fast Track and Orphan Drug designations underscores the ongoing need for new therapeutic options in gMG, a condition characterised by fluctuating and sometimes severe muscle weakness.
This news item has been summarised using AI and checked by humans before publication.
| Sign up for our online community for neurology specialists |
Sources
Merck press release

